Biocon to acquire biosimilars business from Viatris

Home/Pharma News | Posted 01/04/2022 post-comment0 Post your comment

India-based biologicals specialist Biocon Biologics (Biocon) announced on 28 February 2022 that it has entered into a definitive agreement with its partner Viatris (formerly Mylan) to acquire the latter’s biosimilar business.

01 AA007239

Under the terms of the agreement, Biocon will pay Viatris up to US$3.335 billion to acquire the biosimilar business. A move that, according to Biocon, will ‘create a unique fully integrated global biosimilars enterprise’.

The deal gives Biocon a comprehensive portfolio comprising its current range of commercialized insulins, oncology and immunology biosimilars, as well as several other biosimilar assets currently under development.

Biocon and Viatris are already exclusive partners on a broad portfolio of biosimilars. In fact, the pair recently launched two versions of their interchangeable biosimilar Semglee (insulin glargine) in the US [1].

Biocon has also partnered with Indian biologicals specialist vaccine Serum Institute Life Sciences, a subsidiary of Serum Institute of India, giving it access to a 100 million doses of vaccines per annum for 15 years [2].

According to Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics, this latest deal with Viatris is expected to enable Biocon to strengthen its presence in Europe and the US, helping it build a strong global brand and making it future ready for the next wave of products.

Related article
Interchangeable insulin glargine biosimilars available through Prime Therapeutics and Walgreen


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Nomenclatura de biológicos y biocomparables en México

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Nomenclatura de biológicos y biocomparables en México

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Viatris/Biocon launch two versions of Semglee to accommodate rebates []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 1]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Biocon Biologics and Serum Institute Life Sciences partnership []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 1]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

Source: Biocon

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010